Rigel Pharmaceuticals (RIGL) Competitors $17.07 -1.38 (-7.48%) (As of 04:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RIGL vs. MYGN, INVA, OPK, IRWD, SGMO, EBS, CDXS, XOMA, VNDA, and VSTMShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Myriad Genetics (MYGN), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Emergent BioSolutions (EBS), Codexis (CDXS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), and Verastem (VSTM). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Myriad Genetics Innoviva OPKO Health Ironwood Pharmaceuticals Sangamo Therapeutics Emergent BioSolutions Codexis XOMA Vanda Pharmaceuticals Verastem Myriad Genetics (NASDAQ:MYGN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Is MYGN or RIGL more profitable? Rigel Pharmaceuticals has a net margin of 2.46% compared to Myriad Genetics' net margin of -14.09%. Myriad Genetics' return on equity of -4.51% beat Rigel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Myriad Genetics-14.09% -4.51% -3.07% Rigel Pharmaceuticals 2.46%-14.80%3.03% Do insiders & institutionals believe in MYGN or RIGL? 99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.1% of Myriad Genetics shares are owned by insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in MYGN or RIGL? Myriad Genetics received 8 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 52.99% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformMyriad GeneticsOutperform Votes46952.99% Underperform Votes41647.01% Rigel PharmaceuticalsOutperform Votes46168.81% Underperform Votes20931.19% Do analysts rate MYGN or RIGL? Myriad Genetics presently has a consensus price target of $24.27, indicating a potential upside of 75.63%. Rigel Pharmaceuticals has a consensus price target of $36.20, indicating a potential upside of 96.21%. Given Rigel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Myriad Genetics 3 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more risk & volatility, MYGN or RIGL? Myriad Genetics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Which has better valuation & earnings, MYGN or RIGL? Rigel Pharmaceuticals has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyriad Genetics$823.60M1.53-$263.30M-$1.30-10.63Rigel Pharmaceuticals$157.47M2.06-$25.09M$0.14131.79 Does the media refer more to MYGN or RIGL? In the previous week, Myriad Genetics had 8 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 12 mentions for Myriad Genetics and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.40 beat Myriad Genetics' score of 0.08 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryRigel Pharmaceuticals beats Myriad Genetics on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.69M$6.71B$5.04B$8.94BDividend YieldN/A3.06%4.83%4.06%P/E Ratio121.9410.54133.9116.95Price / Sales1.91268.031,148.46127.83Price / CashN/A57.1640.5637.95Price / Book-10.415.194.754.71Net Income-$25.09M$151.85M$118.62M$225.30M7 Day Performance-12.60%-7.81%12.00%-3.74%1 Month Performance-24.93%-1.36%12.07%4.48%1 Year Performance37.66%12.20%31.52%18.72% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals4.2793 of 5 stars$17.07-7.5%$36.20+112.1%+43.0%$300.69M$157.47M121.94147MYGNMyriad Genetics4.5662 of 5 stars$14.14-2.0%$24.27+71.7%-33.4%$1.29B$823.60M-11.102,700INVAInnoviva2.1507 of 5 stars$18.54-0.2%N/A+18.6%$1.16B$310.46M26.93112Short Interest ↓OPKOPKO Health4.4515 of 5 stars$1.55-2.8%$2.75+78.0%+4.2%$1.05B$711.41M-8.343,930Positive NewsIRWDIronwood Pharmaceuticals4.1063 of 5 stars$3.55+0.6%$10.40+193.0%-68.3%$568.11M$442.73M-117.67220SGMOSangamo Therapeutics1.9033 of 5 stars$2.49+21.5%$7.00+181.1%+579.4%$519.54M$176.23M-3.11480Analyst UpgradeHigh Trading VolumeEBSEmergent BioSolutions4.1675 of 5 stars$8.89+4.8%$14.00+57.5%+268.9%$481.70M$1.09B-2.071,600CDXSCodexis4.2441 of 5 stars$5.63+1.8%$8.33+48.0%+95.5%$458.16M$64.45M-6.36250Positive NewsXOMAXOMA4.4149 of 5 stars$27.40+0.9%$81.50+197.4%+72.3%$322.77M$4.76M-7.8010VNDAVanda Pharmaceuticals4.312 of 5 stars$4.66+1.1%$15.50+232.6%+21.9%$271.72M$190.86M-16.54203VSTMVerastem3.6237 of 5 stars$4.71+5.1%$12.50+165.4%-39.6%$209.63M$10M-1.4050News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Myriad Genetics Alternatives Innoviva Alternatives OPKO Health Alternatives Ironwood Pharmaceuticals Alternatives Sangamo Therapeutics Alternatives Emergent BioSolutions Alternatives Codexis Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Verastem Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RIGL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RIGL Stock Alerts